At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 800 target
Drug / intervention
Quetiapine Fumarate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder
In Brief
A Phase 3 clinical trial evaluating Quetiapine Fumarate and Escitalopram oxylate for Generalized Anxiety Disorder. Completed, enrolled 800 participants across 63 sites.
Detailed Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedMay 2006
Study CompletionSep 2007
TodayJul 2026
First PostedMay 24, 2006
Enrollment StartApr 1, 2006
Study CompletionSep 1, 2007
TodayJul 2, 2026
Posted 20.1 years ago
Interventions
Quetiapine Fumaratedrug
Escitalopram oxylatedrug